Generic placeholder image

Current Organic Chemistry

Editor-in-Chief

ISSN (Print): 1385-2728
ISSN (Online): 1875-5348

Characterization and Preclinical Perspectives of Organic Small Molecule Drug Metabolites in Drug-drug Interactions

Author(s): Liqian Gao, Jun Chen, Yi Hu, Hongyan Sun, Yong Siang Ong, Jingxin Zhang, Zhifang Chai and Su Seong Lee

Volume 20, Issue 17, 2016

Page: [1827 - 1834] Pages: 8

DOI: 10.2174/1385272820666151102212542

Price: $65

Abstract

The potential of metabolites to contribute to drug-drug interactions (DDIs) has not been well defined so far. However, metabolites of parent drug compounds can contribute to both side effects and DDIs. To address this unmet challenge, we introduce recent advances as well as our perspectives of the metabolites in DDIs in this review. Firstly, we review several typical examples of organic small molecule drug metabolites asmajor contributors to DDIs in clinic. Since some of the metabolites are so important in the contributions to DDIs, we then further review how to identify active metabolites in vivo and when such metabolites should trigger DDI assessment. Lastly, we review in vivo animal models, especially humanized/chimeric mice, in improving the quality of preclinical DDI assessments.

Keywords: Bupropion, drug-drug interactions (DDIs), gemfibrozil, metabolites, pharmacodynamics, pharmacokinetics.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy